Compare Amgen, Inc. (AMGN) vs Diamondback Energy Inc (FANG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Diamondback Energy Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Diamondback Energy Inc trades at $186.23 (market cap $51.59B). The key difference: Amgen, Inc. is far larger — about 3.8× Diamondback Energy Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | FANG | |
|---|---|---|
Market Cap | $196.12B | $51.59B |
Sector | Health | Energy |
52-Week High | $388.16 | $213.69 |
52-Week Low | $271.18 | $134.53 |
Enterprise Value | $241.41B | $65.31B |
Dividend Yield | 2.77% | 2.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Diamondback Energy (FANG) trades at $183.39, up 0.76% on the day, with a bearish technical signal and neutral oscillators. The company reported mixed Q1 2026 earnings, beating estimates with EPS of $4.23 versus $3.74 expected, but missed Q4 2025. Revenue grew to $14.93B in 2025, though net income margin compressed to 1.88%. Analyst consensus remains strongly bullish with a $234.50 price target, while recent news highlights sector volatility amid oil price fluctuations and upcoming Q2 2026 earnings on August 3, 2026.
FANG presents a growth opportunity with strong analyst support and expanding revenue, but faces risks from declining profit margins, high P/E of 187.13, and oil market sensitivity. The stock's 22% upside to consensus target is tempered by execution risks and macroeconomic headwinds, requiring careful monitoring of Q2 earnings and oil price trends for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →
